Pharmacological profile of TCV-309--a potent PAF antagonist.
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension, increased vascular permeability, bronchoconstriction and death. TCV-309 did not cause hemolysis or vascular irritation. TCV-309 showed beneficial effects on experimental endotoxic shock, anaphylactic shock and disseminated intravascular coagulation.
Terashita
Z
Z
Biology Research Laboratory, Takeda Chemical Industries, Ltd, Osaka, Japan.
Takatani
M
M
Nishikawa
K
K
D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D002478:Cells, Cultured; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011726:Pyridinium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D012772:Shock, Septic / Q000188:drug therapy; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; C067430:TCV 309